<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="195247">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00549679</url>
  </required_header>
  <id_info>
    <org_study_id>IPC101939</org_study_id>
    <nct_id>NCT00549679</nct_id>
  </id_info>
  <brief_title>Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety and Tolerability of Inhaled GSK256066 in Mild to Moderate COPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and tolerability of the cfor the first time in mild to
      moderate COPD patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Parameters: Adverse events, 12 Lead Electrocardiogram, Vital Signs, Clinical Laboratory Evaluations,</measure>
    <time_frame>after 28 days repeat dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lung Function Parameters, Holter monitoring, Withdrawals for exacerbations of COPD.</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of GSK256066 and active metabolite GSK614917 and derived pharmacokinetic parameters</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parameters measured in induced sputum: Total cell number (cells/mL); Neutrophils, macrophages, lymphocytes and eosinophils as a percentage of total cells; Absolute numbers of neutrophils, macrophages, lymphocytes and eosinophils</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The concentration of total protein and inflammatory biomarkers in induced sputum supernatant</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in messenger ribonucleic acid (mRNA) and/or protein in induced sputum of established and exploratory markers of inflammation and established and exploratory pharmacodynamic markers</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function parameters (pre and post-bronchodilator)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometry measures: FEV1, FVC Plethysmography measures Impulse oscillometry The concentration of serum inflammatory biomarkers</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function Parameters Holter monitoring Withdrawals for exacerbations of COPD</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>25 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 microgram inhaled once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>87.5 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>87.5 microgram inhaled once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo inhaled once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK256066</intervention_name>
    <description>PDE4 inhibitor</description>
    <arm_group_label>25 mcg</arm_group_label>
    <arm_group_label>87.5 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male adults or female adults of non-childbearing potential who are between 40 and 75
             years of age (inclusive).

          -  Subjects with a clinical diagnosis of COPD in accordance with the European
             Respiratory Society Consensus Statement and subjects categorised with moderate COPD
             as defined by the GOLD guidelines of 2006 [GOLD, 2006]

          -  Subjects with a cigarette smoking history of ≥ 10 pack years (1 pack year = 20
             cigarettes smoked per day for 1 year or the equivalent). Both current and former
             smokers are eligible to be enrolled. A former smoker is defined as a subject who has
             not smoked for ≥6 months at Visit 1.

          -  Subjects with a post-bronchodilator FEV1 to FVC ratio (FEV1/FVC) &lt; 0.7 at Visit 1.
             Subjects will be assessed 30 (± 5) minutes after receiving salbutamol 400 μg.

          -  Subjects with a post-bronchodilator FEV1 ≥ 50% and &lt; 80% of predicted normal for
             height, age and sex at Visit 1. Subjects will be assessed 30 (± 5) minutes after
             receiving salbutamol 400 μg.

          -  Subjects with a normal echocardiogram at screening, as defined by the absence of
             clinically significant wall motion, chamber size or valvular abnormalities

          -  The subject must be capable of giving informed consent and can comply with the study
             requirements and timetable.

        Exclusion Criteria:

          -  Women who are pre-menopausal and of child-bearing potential.

          -  Subjects weighing less than 50 kilograms (kg).

          -  Subjects who are obese defined as having a body mass index (BMI) &gt; 30.

          -  Subjects with a current diagnosis of asthma.

          -  Subjects who have required hospitalisation or treatment with oral corticosteroids
             and/or antibiotic therapy for acute worsening of COPD or lower respiratory tract
             infection in the 6 weeks prior to Screening.

          -  Subjects who have received treatment with oral, intravenous, topical or
             intra-articular corticosteroids within 6 weeks of Screening or thereafter

          -  Subjects with active tuberculosis, sarcoidosis or clinically overt bronchiectasis.

          -  Subjects with a history of any type of malignancy with the exception of successfully
             treated squamous cell cancer of the skin.

          -  Subjects with rheumatoid arthritis, connective tissue disorders and other conditions
             known to be associated with chronic inflammation (e.g. Inflammatory Bowel Disease).

          -  Subjects with chronic infections (lasting longer than 6 months) such as gingivitis,
             periodontitis, prostatitis, gastritis, and urinary tract infections.

          -  Subjects with any acute infection, sinus symptoms, or significant trauma (burns,
             fractures).

          -  Subjects with clinically significant renal disease, diabetes mellitus/metabolic
             syndrome, hypertension or any other clinically significant cardiovascular,
             neurological, endocrine, or haematological abnormalities that are uncontrolled on
             permitted therapy.

          -  Subjects who have participated in any GSK study/studies involving administration of
             COA.

          -  The subject has a screening ECG parameters outside of ranges specified in protocol.

          -  Subjects with hypoxaemia

          -  Risk factors for human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C
             infection at Screening (Visit 1).

          -  Subjects who have undergone surgery including lung volume reduction surgery in the
             last six months or have conditions that prevent them from performing spirometry.

          -  Subjects with a history (or suspected history) of alcohol misuse or any other
             recreational substance abuse.

          -  Subjects who require treatment with any of the following from the start of the run-in
             period (Day -14) until the end of the treatment phase:

          -  Inhaled corticosteroids

          -  Inhaled cromolyn sodium or nedocromil

          -  Xanthines (theophylline preparations).

          -  Leukotriene modifiers

          -  Tiotropium

          -  Long-acting inhaled beta2-agonists (salmeterol, formoterol)

          -  Oral beta2-agonists

          -  Subjects who are unable to abstain from other courses of medication during the run in
             phase including non-steroidal anti-inflammatory drugs (NSAIDs), anti-depressant
             drugs, anti-histamines, anti-rhinitis or hay fever medication, other than short
             acting inhaled beta-agonists, ipratropium bromide and paracetamol (up to 4 g per day)
             for the treatment of minor ailments (eg headache) from 48h before the first dose
             until the follow-up visit. Subjects requiring medication between dosing and follow up
             may be excluded at the principal investigators discretion.

          -  Subjects with any known hypersensitivity to salbutamol or ipratropium bromide.

          -  Subjects who are participating or plan to participate in the active phase of a
             pulmonary rehabilitation programme during the study.

          -  Subjects who have received an investigational drug within 30 days or within five drug
             half-lives of the investigational drug (whichever is longer).

          -  Subjects with any clinically relevant abnormality detected by the assessments at
             Screening.

          -  Subjects who have experienced an exacerbation during the run-in period requiring
             treatment with oral corticosteroids and/or macrolide antibiotics and/or
             hospitalisation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gauting</city>
        <state>Bayern</state>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10717</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22291</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hoorn</city>
        <zip>1624 NP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Horn</city>
        <zip>6085 NM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Veldhoven</city>
        <zip>5504 DB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barnaul</city>
        <zip>656 045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>105 077</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
  </location_countries>
  <removed_countries>
    <country>New Zealand</country>
    <country>Slovakia</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 25, 2012</lastchanged_date>
  <firstreceived_date>October 24, 2007</firstreceived_date>
  <firstreceived_results_disposition_date>November 30, 2009</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease (COPD)</keyword>
  <keyword>COPD</keyword>
  <keyword>Repeat Dose</keyword>
  <keyword>GSK256066</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>6-((3-((dimethylamino)carbonyl)phenyl)sulfonyl)-8-methyl-4-((3-methyloxyphenyl)amino)-3-quinolinecarboxamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
